News Releases

Select year
Categories

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer 

Mar 17, 2026 | Products

Read more

Myriad Commercially Launches Precise MRD with Select Community Oncologists

Mar 02, 2026 | Products

Read more

Six presented abstracts at ASCO-GU 2026 reinforce the clinical impact of Myriad’s Precise MRD, Prolaris, and MyRisk tests

Feb 24, 2026 | Products

Read more

Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Feb 23, 2026 | Corporate | Financial

Read more

FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test

Feb 19, 2026 | Products

Read more

Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

Feb 16, 2026 | Corporate | Financial

Read more

Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

Jan 27, 2026 | Products

Read more

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance

Jan 12, 2026 | Corporate | Financial

Read more

Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Jan 05, 2026 | Corporate | Financial

Read more